Amgen and Regeneron Emerge as GLP-1 Leaders Amid Surge in Demand

The pharmaceutical industry is witnessing a surge in demand for GLP-1 (glucagon-like peptide-1) medications, which are traditionally used to treat diabetes but are now being approved for other conditions such as obesity and obstructive sleep apnea. According to recent data, Amgen and Regeneron are two biotech companies that could benefit from this trend.

Amgen is developing a highly differentiated GLP-1 product called MariTide, which is currently in phase 3 clinical trials for weight management, diabetes, and several other conditions. If approved, MariTide could be administered monthly or less frequently, providing a significant advantage over daily or weekly anti-obesity treatments. Amgen's pipeline beyond MariTide is also promising, with the company expected to make significant clinical progress in the next few years.

Regeneron, on the other hand, has a pair of promising GLP-1 candidates in the pipeline, including olatorepatide, a dual GLP-1 and GIP agonist that has shown promising results in a phase 3 study conducted in China. The medicine led to a mean weight loss of up to 19% over 48 weeks, comparable to Eli Lilly's Zepbound, which posted a mean weight loss of 20.2% in a similar study.

Both Amgen and Regeneron have been performing well financially, with revenue increases of 10% and 17%, respectively, year-over-year. The companies' adjusted earnings per share (EPS) have also been impressive, with Amgen's EPS increasing by 4% and Regeneron's EPS increasing by 11%. With a strong pipeline and growing demand for GLP-1 medications, these two biotech companies are well-positioned to benefit from the trend.